CorMedix Inc reports results for the quarter ended in January - Earnings Summary

CorMedix

14/08/2024 14:51

* CorMedix Inc  CRMD.OQ  reported a quarterly adjusted loss
of 25
cents​​ per share for the quarter ended in January, identical to
the same quarter last year.  The mean expectation of
four analysts for the quarter was for a loss of 25 cents per
share. Wall Street expected results to range from -27 cents
to -23 cents per share.
    * Revenue was $806.12 thousand​; analysts expected $1.67
million. 
    * CorMedix Inc's reported EPS for the quarter was a loss
of 25
cents​.
    * The company reported a quarterly loss of $14.15 million.
    * CorMedix Inc shares had fallen by 12.7% this quarter and
gained 0.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for CorMedix Inc is
$11.00 
This summary was machine generated from LSEG data August 14 at
01:51 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.25          -0.25          Met
 Mar. 31 2024      -0.28          -0.25          Beat
 Dec. 31 2023      -0.20          -0.26          Missed
 Sep. 30 2023      -0.21          -0.17          Beat